BioLineRx has been granted a patent for a method using engineered oncolytic viruses to treat cancer. The method involves delivering an enzyme to modify cancer cell glycosylation and inducing cell lysis through direct injection, aiming to enhance anti-tumor immunity. GlobalData’s report on BioLineRx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on BioLineRx, Peptide pharmacophores was a key innovation area identified from patents. BioLineRx's grant share as of July 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Oncolytic virus compositions for cancer treatment and immunity
The patent US12023362B2 outlines a method for inducing an immune response in individuals with tumors through the use of an oncolytic virus. The method involves expressing an endogenous enzyme, specifically an alpha 1,3-galactosyltransferase, within cancer cells. This expression modifies the glycosylation of the cell membrane, which is followed by the lysis of the cancer cells due to the administration of the oncolytic virus via direct injection into the tumor. The claims emphasize the importance of delivering the virus in an effective amount to ensure it infects the targeted cancer cells, thereby enhancing the immune response against the tumor.
Further claims detail specific characteristics of the oncolytic virus, including its potential to be replication restricted and its classification as either an RNA or DNA virus, with adenoviruses being a notable example. The patent specifies the use of a conditionally replicating adenovirus (CRAd), particularly an Ad5/3 chimeric virus, which may include a 24-base pair deletion in the viral gene. Additionally, the method aims to induce a protective anti-tumor immune response, reinforcing the therapeutic potential of the described approach in treating individuals suffering from cancer or tumors.
To know more about GlobalData’s detailed insights on BioLineRx, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
